Expanded Labelling For Januvia(R) (Sitagliptin) Approved By European Commission

January 22nd, 2008 | Category: Diabetes

Merck Sharp & Dohme (MSD) announced that the European Commission has approved ‘Januvia’ (sitagliptin) for two additional uses for patients with type 2 diabetes. that now makes sitagliptin the only dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) approved as an add-on therapy to

a sulphonylurea (’dual therapy’), or a sulphonylurea plus metformin (’triple therapy’), in the European Union (EU). It remains the only DPP-4 inhibitor indicated for once-daily use.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • FDA Approves New Uses For Januvia Diabetes Drug
  • Diabetes UK Calls For Traffic-light Food Labelling
  • European Commission Approves GSK’s Experimental HPV Vaccine Cervarix For Sale In E.U. Countries
  • European Commission Announces Marketing Authorisation For 50mg Once Weekly Enbrel(R) For Patients With Moderate-To-Severe Psoriasis
  • Wyeth’s TORISEL Receives European Commission Approval For The Treatment Of Advanced Kidney Cancer

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.